Hematopoietic Cell Growth Factors
- Hematopoietic Cell Growth Factors
- Accession Number
These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.
Drug Drug Description Darbepoetin alfa A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Erythropoietin A recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia. Pegfilgrastim A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. Sargramostim A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Filgrastim A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. Thrombopoietin Investigated for use/treatment in thrombocytopenia. Ancestim A human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection. Methoxy polyethylene glycol-epoetin beta A synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. Epoetin delta Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo. Muplestim Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in... Molgramostim Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Lenograstim A granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors. Lipegfilgrastim A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Regramostim Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant. Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Eflapegrastim Eflapegrastim is under investigation in clinical trial NCT02953340 (Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide...
- Drugs & Drug Targets